Ryan & Maniskas, LLP Announces Investigation of DUSA Pharmaceuticals Inc.

  Ryan & Maniskas, LLP Announces Investigation of DUSA Pharmaceuticals Inc.

Business Wire

WAYNE, Pa. -- November 09, 2012

Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/dusa) is investigating
potential claims against the board of directors of DUSA Pharmaceuticals Inc.
(“DUSA” or the “Company”) (NASDAQ: DUSA) for potential breaches of fiduciary
duties in connection with their conduct related to the sale of the Company to
Sun Pharmaceutical Industries Limited in an all-cash deal valued at
approximately $230 million.

Our investigation concerns possible breaches of fiduciary duty and other
violations of law related to the approval of the transaction by the Company’s
board of directors; in particular, whether the Company undertook a fair
process to obtain fair consideration for all shareholders of DUSA. For more
information regarding our investigation, please contact Ryan & Maniskas, LLP
(Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at
rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/dusa

Under the terms of the proposed transaction, DUSA’s stockholders will receive
$8 in cash for each share of DUSA common stock they own.

If you own shares of DUSA and would like to learn more about these claims or
if you wish to discuss these matters and have any questions concerning this
announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at
(877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/dusa. You
may also email Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information
about class action cases in general, please visit our website:

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan &
Maniskas, LLP is devoted to protecting the interests of individual and
institutional investors in shareholder actions in state and federal courts


Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
Press spacebar to pause and continue. Press esc to stop.